News & Events

Statement from The Association for Frontotemporal Degeneration (AFTD) on Disruption of Scientific Research Funding and Activities

The Association for Frontotemporal Degeneration (AFTD) is deeply concerned about recent policy changes and layoffs at the National Institutes of Health (NIH) that greatly disrupt biomedical research of high importance…

MORE

Guest Feature: The Story Behind the Story – Our Journey Through FTD and Why I Wrote “Welcome to the Honey B & B”

Novelist Melody Carlson drew from her family’s FTD story to write her latest book, Welcome to the Honey B & B, which will be released on March 4 by Baker…

MORE

AFTD Webinar: At the Intersection of FTD and the Law

FTD can present with executive dysfunction, impulsivity, loss of empathy, apathy, and disinhibition. At times, these symptoms can lead to interactions with police, whether responding to an incident at home…

MORE

Passage Bio Announces Interim Data for UpliFT-D Trial for FTD-GRN

Biotechnology company Passage Bio released interim data for its upliFT-D clinical trial for its gene replacement therapy for FTD-GRN and announced that it is on track to expand the trial…

MORE

Advocacy Update: Protect FTD Research Today!

Calling all AFTD advocates – federal funding for FTD research is at risk, and we need your advocacy to protect it. Earlier this month, the National Institutes of Health announced…

MORE

FTD Researchers Call for Greater Focus on Diversity to Address Disparities in Care and Research

An article published in the journal Alzheimer’s & Dementia identifies gaps in current FTD research caused by disparities in access to proper dementia care and research centers, and outlines ways…

MORE

The Lived Experience of FTD: FTD and Intimacy

In the following article, Anne Fargusson, RN, a member of the Persons with FTD Advisory Council, writes about intimacy and FTD. Intimacy can be an uncomfortable word. Years ago, when…

MORE

Vesper Bio Clinical Trial for FTD-GRN Enters Phase Ib/IIa

Danish biotechnology company Vesper Bio announced in January that its clinical trial for a potentially disease-modifying drug for FTD-GRN is proceeding to phase Ib/IIa. In FTD caused by an inherited…

MORE